Abstracts tagged "interleukins (IL)"

Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…
Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting
Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation
Ludmila Kelly, Vilma Decman and Dimitris Skokos, Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
Abstract Number: 2119 • 2012 ACR/ARHP Annual Meeting
Interleukin-6 As a Biomarker for the Clinical and Radiological Effectiveness of Methotrexate in Rheumatoid Arthritis
Naoshi Nishina, Hideto Kameda, Yuko Kaneko, Masataka Kuwana and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is now an anchor drug in the treatment strategy of rheumatoid arthritis (RA) and its effectiveness has been established. However it is…
Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting
IL-6 and IL-21 in Rheumatoid Arthritis
Gustavo Carbone¹, Augusta Wilson¹, Sean Diehl², Janice Bunn³, Sheldon Cooper⁴ and Mercedes Rincon⁵, ¹Rheum & Clinical Imm Unit, University of Vermont College of Medicine, Burlington, VT, ²Immunobiology, University of Vermont College of Medicine, ³Mathematics and Statistics, University of Vermont, Burlington, VT, ⁴Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT, ⁵Immunobiology, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…
Abstract Number: 21 • 2012 ACR/ARHP Annual Meeting
IL-32 and IL-17 Interact and Aggravate Osteoclastogenesis in Rheumatoid Arthritis
Bo Young Yoon¹, Young-Mee Moon², Yang-Mi Her², Hye Jwa Oh², Jae-Seon Lee², Kyoung-Woon Kim³, Seon-Yeong Lee², Yun-Ju Woo², Kyung-Su Park², Sung-Hwan Park⁴, Ho-Youn Kim² and Mi-La Cho², ¹Inje University Ilsan Paik Hospital, Goyang, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ³Conversant Research Consortium in Immunologic disease, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
Background/Purpose: Interleukin (IL)-32 and IL-17 play critical roles in pro-inflammatory responses and are highly expressed in the synovium of patients with rheumatoid arthritis (RA). We…
Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting
ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Shunji Yamazaki¹, Masamichi Inami¹, Misato Ito¹, Yasutomo Fujii¹, Kaori Hanaoka¹, Kaoru Yamagami¹, Kenji Okuma¹, Yoshiaki Morita¹, Shohei Shirakami², Takayuki Inoue², Susumu Miyata³ and Yasuyuki Higashi¹, ¹Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ²Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ³Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
Abstract Number: 1062 • 2012 ACR/ARHP Annual Meeting
Identification of Highly Potent and Selective Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for the Treatment of Rheumatic Diseases
Divya Chaudhary¹, Shaughnessy Robinson², Craig E. Masse¹, Matthew D. Wessel², Shawn Watts², Jeremy Greenwood², Mee Shelley², Mark Brewer², Geraldine Harriman¹, Leah L. Frye², Ronald T. Wester¹, Rosana Kapeller¹ and Donna Romero¹, ¹25 First Street Suite 404, Nimbus Discovery, Inc., Cambridge, MA, ²Schrödinger, Inc., New York, NY
Background/Purpose: Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of the innate immune response orchestrated by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), IL-33…
Abstract Number: 2677 • 2012 ACR/ARHP Annual Meeting
IL-23 Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 Mice
Hao Li¹, Hui-Chen Hsu², Qi Wu³, PingAr Yang³, Jun Li⁴, Daniel Cua⁵, Mohamed Oukka⁶ and John D. Mountz⁷, ¹Microbiology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁶Pediatrics, Seattle, WA, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Failure to clear apoptotic bodies is a central pathogenic mechanism for SLE. We have observed that spontaneous systemic autoimmunity and lupus in BXD2 mice…
Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Miho Suzuki¹, Hiroto Yoshida², Misato Hashizume¹, Masashi Shiina², Keisuke Tanaka¹ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
Abstract Number: 894 • 2012 ACR/ARHP Annual Meeting
Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts
A. Krabben¹, A. G. Wilson², R. Knevel¹, A. Zhernakova³, E. Brouwer³, E. Lindqvist⁴, T. Saxne⁴, G. Stoeken-Rijsbergen¹, J. A. B. van Nies¹, D. P. C. de Rooy¹, T.W.J. Huizinga¹, B. P. C. Koeleman⁵, R. E. M. Toes¹, P. K. Gregersen⁶ and A. H. M. van der Helm-van Mil¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁴Rheumatology, Lund University, Lund, Sweden, ⁵Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY
Background/Purpose: The severity of RA is reflected by the severity of radiological joint destruction. It is highly variable between patients and up to 58% of…
Abstract Number: 2684 • 2012 ACR/ARHP Annual Meeting
Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 Antibodies As Surrogate Markers for CNS Disease Severity in SLE
Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestations occur in approximately one-half of patients with SLE and may cause substantial impairment of quality of life as well as disability. Among…
Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Hiroto Yoshida¹, Miho Suzuki¹, Misato Hashizume¹, Keisuke Tanaka², Masashi Shiina², Isao Matsumoto³, Takayuki Sumida³ and Yoshihiro Matsumoto², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, ³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
Abstract Number: 899 • 2012 ACR/ARHP Annual Meeting
A Role for Soluble Interleukin-6 Receptor As an Antagonist of Interleukin-27 Signaling
Misato Hashizume¹, Keiko Esaki² and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Recently, it has been reported that interleukin (IL)-27 treatment reduces inflammation and ameliorates arthritis in collagen-induced arthritis mice. IL-27 is a heterodimeric cytokine composed…
Abstract Number: 2021 • 2012 ACR/ARHP Annual Meeting
The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome Is Driven by the Phenotype Severity Rather Than the Age
Roberta Caorsi¹, Loredana Lepore², Francesco Zulian³, Maria Alessio⁴, Achille Stabile⁵, Antonella Insalaco⁶, Martina Finetti¹, Antonella Battagliese⁴, Giorgia Martini⁷, Chiara Bibalo⁸, Alberto Martini⁹ and Marco Gattorno¹, ¹Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, ²Istituto Burlo Garofolo, Trieste, Italy, ³Department of Pediatrics, University of Padua, Padova, Italy, ⁴Department of Pediatrics,, Federico II Hospital, Napoli, Italy, ⁵DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, ⁶Department of Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Department of Pediatrics,, University of Padua, Padua, Italy, ⁸Pediatrics-Univ of Trieste, Ospedale-Infantile Trieste, Trieste, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: to identify the optimal regimen for the treatment with Canakinumab in CAPS patients and, in patients receiving both Anakinra and Canakinumab during their disease…
Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].